Verona Pharma's VRNA short percent of float has fallen 11.62% since its last report. The company recently reported that it ...

Verona Pharma (VRNA) is showing exceptional technical strength, hitting a new high in morning trading on June 24. ・The stock has a 100% technical “Buy” signal via Barchart. ・The stock has surged 515% ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma PLC ADR research and ratings by Barron's. View VRNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised ...

Cantor Fitzgerald analysts on Wednesday maintained their Overweight rating and $100.00 price target on Verona Pharma (NASDAQ: VRNA) stock.According to InvestingPro data, the stock currently has a ...

With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide.

BOSTON, June 10, 2025 /PRNewswire/ -- Curadev Pharma, Inc., a clinical-stage biotechnology company developing novel immuno-oncology therapeutics, and Memorial Sloan Kettering Cancer Center (MSK ...